Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

There is no known cure for Tardive Dyskinesia, a serious movement disorder linked to some psychiatric drugs and metoclopramide, a medication used to treat heartburn, GERD, and other gastrointestinal disorders. The condition, identified by involuntary movements such as jerks, eye blinking, and muscle contractions of the face and limbs, usually develops after long-term use of the medications. Symptoms often persist even after the medication has been stopped. Use of the drugs that cause Tardive Dyskinesia also can mask symptoms, which can mean symptoms become more pronounced after the medication stops.

Medications most often associated with Tardive Dyskinesia include metoclopramide, known in the U.S. by the brand names Reglan and Metozolv, and psychiatric drugs Thorazine, Stelazine, Haldol, Prolixin, Zyprexa, Risperdal and Clozaril.

While nothing seems to cure the condition, some treatments have been shown to bring relief to sufferers. Those treatments include:

- Vitamin E may have some beneficial effects on patients, especially those who have not yet developed Tardive Dyskinesia. Since large doses of vitamin E can be toxic, it is recommended that patients consult with their doctors before adding supplemental vitamin E to their diets.
- Botulinum toxin injections (BTX), also known as BOTOX therapy, has been shown to relieve symptoms that involved limited groups of muscles. Consult with your doctor to see if this form of treatment is right for you.
- Some medications have been used to successfully treat Tardive Dyskinesia. Talk with your doctor about options in drug therapy.

If you suffer from Tardive Dyskinesia, or are experiencing any unusual and involuntary movements, and take or have taken metoclopramide or any psychiatric drugs, you are encouraged to seek specialized medical treatment.

Source: National Empowerment Center

Related posts:

• Few resources available for those with Tardive Dyskinesia
• Salix metoclopramide drug moves closer to FDA approval
• Clinical trials seek treatment for Tardive Dyskinesia
• Salix plans to increase sales force to push new gastroparesis drug
• Study: 20 percent of long-term Reglan users develop Tardive Dyskinesia

This entry was posted on Thursday, October 1st, 2009 at 7:00 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.